Sign in or create an account to add this stock to your watchlist.
About Aquinox Pharmaceuticals (NASDAQ:AQXP)
Aquinox Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. Its lead product candidate is Rosiptor (Leadership 301), a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aquinox Pharmaceuticals, Inc. in January 2014. Aquinox Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AQXP
CUSIPN/A
Phone604-629-9223
Debt
Debt-to-Equity RatioN/A
Current Ratio10.08
Quick Ratio10.08
Price-To-Earnings
Trailing P/E Ratio-5.87
Forward P/E Ratio-5.53
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.65 per share
Price / Book3.44
Profitability
EPS (Most Recent Fiscal Year)($2.14)
Net Income$-50,180,000.00
Net MarginsN/A
Return on Equity-53.37%
Return on Assets-49.03%
Miscellaneous
Employees51
Outstanding Shares23,510,000
Aquinox Pharmaceuticals (NASDAQ:AQXP) Frequently Asked Questions
What is Aquinox Pharmaceuticals' stock symbol?
Aquinox Pharmaceuticals trades on the NASDAQ under the ticker symbol "AQXP."
How were Aquinox Pharmaceuticals' earnings last quarter?
Aquinox Pharmaceuticals (NASDAQ:AQXP) released its quarterly earnings results on Tuesday, May, 8th. The company reported ($0.62) EPS for the quarter, topping analysts' consensus estimates of ($0.70) by $0.08. View Aquinox Pharmaceuticals' Earnings History.
When is Aquinox Pharmaceuticals' next earnings date?
What price target have analysts set for AQXP?
4 brokers have issued twelve-month price targets for Aquinox Pharmaceuticals' shares. Their forecasts range from $22.00 to $28.00. On average, they expect Aquinox Pharmaceuticals' stock price to reach $25.25 in the next twelve months. View Analyst Ratings for Aquinox Pharmaceuticals.
What are Wall Street analysts saying about Aquinox Pharmaceuticals stock?
Here are some recent quotes from research analysts about Aquinox Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. " (5/15/2018)
- 2. Needham & Company LLC analysts commented, "Aquinox reported 1Q18 financial results today and we spoke with mgmt for an update. The rosiptor Phase 3 LEADERSHIP trial in Interstitial Cystitis (IC)/ Bladder Pain Syndrome (BPS) remains on track for top-line results in 3Q18, most likely in July. 12wk trial was completed in Feb 2018. We expect a positive outcome based on Phase 2 data. Mgmt plans to revisit Phase 3 design w/ FDA prior to initiation of a planned second Phase 3 trial, which we believe may begin around YE18. Patient screening in a Phase 2 trial of rosiptor in Chronic Prostatitis (CP/ CPPS) is underway. Reiterate BUY. We do not believe the stock adequately reflects value of rosiptor program in BPS/IC." (5/8/2018)
- 3. Cantor Fitzgerald analysts commented, "R&D day provided contemporary thoughts about IC/BPS and how rosiptor could address an unmet need. We attended an R&D day hosted by AQXP in NYC on Friday, Feb. 9 (presentation here). The company included Dr. Phillip Hanno (Clinical Prof, Stanford U.) on the program to provide a KOL viewpoint of interstitial cystitis/bladder pain syndrome (IC/BPS) and the treatment of it." (2/11/2018)
- 4. Canaccord Genuity analysts commented, "We recently hosted a call with Dr. J. Quentin Clemens, chief of the Division of Neurourology and Pelvic Reconstruction, urology director for female pelvic medicine and professor of urology at the University of Michigan. While Dr. Clemens has not used AQXP’s rosiptor (AQX-1125), his discussion of IC/BPS provided us with more confidence in the design of the ongoing, pivotal Ph3 LEADERSHIP 301 assessing rosiptor in IC/BPS patients, which remains on track to complete enrollment in 1Q18 and for top-line data in 3Q18. We reiterate our BUY rating." (12/19/2017)
Who are some of Aquinox Pharmaceuticals' key competitors?
Some companies that are related to Aquinox Pharmaceuticals include Retrophin (RTRX), Revance Therapeutics (RVNC), Apellis Pharmaceuticals (APLS), Mirati Therapeutics (MRTX), Athenex (ATNX), Esperion Therapeutics (ESPR), Lexicon Pharmaceuticals (LXRX), TG Therapeutics (TGTX), Flexion Therapeutics (FLXN), Dynavax Technologies (DVAX), Zai Lab (ZLAB), Alder BioPharmaceuticals (ALDR), Omeros (OMER), Endocyte (ECYT) and Eagle Pharmaceuticals (EGRX).
Who are Aquinox Pharmaceuticals' key executives?
Aquinox Pharmaceuticals' management team includes the folowing people:
- Mr. David J. Main, Co-Founder, Chairman, CEO & Pres (Age 53)
- Mr. Kamran Alam, CFO, VP of Fin. & Corp. Sec. (Age 44)
- Ms. Abigail L. Jenkins, Chief Commercial Officer and U.S. Bus. Head (Age 42)
- Mr. Lloyd Mackenzie, COO & VP of R&D Operations (Age 51)
- Ms. Shelley McCloskey, VP of HR & Admin. (Age 58)
Has Aquinox Pharmaceuticals been receiving favorable news coverage?
News stories about AQXP stock have been trending positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aquinox Pharmaceuticals earned a media sentiment score of 0.26 on Accern's scale. They also gave media headlines about the company an impact score of 45.60 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Aquinox Pharmaceuticals' major shareholders?
Aquinox Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (5.72%), BlackRock Inc. (3.41%), Point72 Asset Management L.P. (1.06%), University of Notre Dame DU Lac (0.59%), DAFNA Capital Management LLC (0.46%) and Dimensional Fund Advisors LP (0.31%). Company insiders that own Aquinox Pharmaceuticals stock include Bros Advisors Lp Baker, Daniel J Levitt, David Main and Lloyd Mackenzie. View Institutional Ownership Trends for Aquinox Pharmaceuticals.
Which major investors are selling Aquinox Pharmaceuticals stock?
AQXP stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., University of Notre Dame DU Lac, Point72 Asset Management L.P. and DAFNA Capital Management LLC. Company insiders that have sold Aquinox Pharmaceuticals company stock in the last year include Daniel J Levitt, David Main and Lloyd Mackenzie. View Insider Buying and Selling for Aquinox Pharmaceuticals.
Which major investors are buying Aquinox Pharmaceuticals stock?
AQXP stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG, Dimensional Fund Advisors LP, GSA Capital Partners LLP, Eversept Partners LLC, Franklin Resources Inc. and Alps Advisors Inc.. View Insider Buying and Selling for Aquinox Pharmaceuticals.
How do I buy shares of Aquinox Pharmaceuticals?
Shares of AQXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aquinox Pharmaceuticals' stock price today?
One share of AQXP stock can currently be purchased for approximately $12.56.
How big of a company is Aquinox Pharmaceuticals?
Aquinox Pharmaceuticals has a market capitalization of $290.80 million. The company earns $-50,180,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis. Aquinox Pharmaceuticals employs 51 workers across the globe.
How can I contact Aquinox Pharmaceuticals?
Aquinox Pharmaceuticals' mailing address is 450-887 GREAT NORTHERN WAY, VANCOUVER A1, V5T 4T5. The company can be reached via phone at 604-629-9223 or via email at [email protected]
MarketBeat Community Rating for Aquinox Pharmaceuticals (AQXP)
MarketBeat's community ratings are surveys of what our community members think about Aquinox Pharmaceuticals and other stocks. Vote "Outperform" if you believe AQXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AQXP will underperform the S&P 500 over the long term. You may vote once every thirty days.
Aquinox Pharmaceuticals (NASDAQ:AQXP) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Aquinox Pharmaceuticals in the last 12 months. Their average twelve-month price target is $25.25, suggesting that the stock has a possible upside of 101.04%. The high price target for AQXP is $28.00 and the low price target for AQXP is $22.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $25.25 | $25.25 | $25.25 | $25.00 |
| Price Target Upside: | 101.04% upside | 64.92% upside | 64.92% upside | 136.52% upside |
Aquinox Pharmaceuticals (NASDAQ:AQXP) Consensus Price Target History
Aquinox Pharmaceuticals (NASDAQ:AQXP) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
Aquinox Pharmaceuticals (NASDAQ:AQXP) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Aquinox Pharmaceuticals (NASDAQ AQXP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.70%
Institutional Ownership Percentage: 90.05%
Aquinox Pharmaceuticals (NASDAQ AQXP) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/14/2018 | Daniel J Levitt | Director | Sell | 3,906 | $12.67 | $49,489.02 | 3,906 |  |
| 3/15/2018 | Lloyd Mackenzie | COO | Sell | 1,302 | $14.63 | $19,048.26 | 1,302 | |
| 6/5/2017 | David Main | Insider | Sell | 15,625 | $13.26 | $207,187.50 | 77,530 | |
| 1/9/2017 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 398,062 | $17.18 | $6,838,705.16 | | |
| 9/20/2016 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 2,783,605 | $12.25 | $34,099,161.25 | | |
| 3/16/2016 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 471,667 | $7.99 | $3,768,619.33 | | |
| 3/15/2016 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 109,912 | $7.98 | $877,097.76 | | |
| 1/26/2016 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 140,786 | $10.80 | $1,520,488.80 | | |
| 1/20/2016 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 112,034 | $9.48 | $1,062,082.32 | | |
| 1/19/2016 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 78,045 | $9.11 | $710,989.95 | | |
| 1/15/2016 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 202,623 | $8.28 | $1,677,718.44 | | |
| 9/10/2015 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 2,480,032 | $15.50 | $38,440,496.00 | | |
| 8/24/2015 | David Chilton Mitchell | VP | Buy | 3,575 | $17.81 | $63,670.75 | 1,600 | |
| 8/12/2015 | Kamran Alam | CFO | Sell | 29,079 | $18.67 | $542,904.93 | | |
| 8/12/2015 | Lloyd Mackenzie | VP | Sell | 35,887 | $18.67 | $670,010.29 | | |
| 12/17/2014 | & Johnson Johnson | Major Shareholder | Sell | 8,100 | $7.62 | $61,722.00 | | |
| 12/12/2014 | & Johnson Johnson | Major Shareholder | Sell | 5,000 | $7.51 | $37,550.00 | | |
| 12/10/2014 | & Johnson Johnson | Major Shareholder | Sell | 8,300 | $7.72 | $64,076.00 | | |
| 12/9/2014 | & Johnson Johnson | Major Shareholder | Sell | 5,000 | $7.73 | $38,650.00 | | |
| 12/8/2014 | & Johnson Johnson | Major Shareholder | Sell | 2,000 | $7.69 | $15,380.00 | | |
| 12/5/2014 | & Johnson Johnson | Major Shareholder | Sell | 15,900 | $7.76 | $123,384.00 | | |
| 12/1/2014 | & Johnson Johnson | Major Shareholder | Sell | 1,200 | $7.54 | $9,048.00 | | |
| 11/26/2014 | & Johnson Johnson | Major Shareholder | Sell | 2,000 | $7.75 | $15,500.00 | | |
| 11/24/2014 | & Johnson Johnson | Major Shareholder | Sell | 9,500 | $8.14 | $77,330.00 | | |
| 3/12/2014 | Pfizer Inc | Major Shareholder | Buy | 272,727 | $11.00 | $2,999,997.00 | | |
(Data available from 1/1/2013 forward)
Aquinox Pharmaceuticals (NASDAQ AQXP) News Headlines
| Source: |
|
Aquinox Pharmaceuticals (NASDAQ:AQXP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Aquinox Pharmaceuticals (NASDAQ:AQXP) Income Statement, Balance Sheet and Cash Flow Statement
Aquinox Pharmaceuticals (NASDAQ AQXP) Stock Chart for Friday, May, 25, 2018
Loading chart…
